The World Health Organization (WHO) granted approval for Indian drugmaker Bharat Biotech’s home-grown Covid-19 vaccine for emergency use listing, paving the way for Covaxin to be accepted as a valid vaccine in many poor countries.
Novavax Inc. and partner Serum Institute of India said on November 1 they received emergency use authorization for their Covid-19 vaccine in Indonesia, making it the first approval anywhere in the world for Novavax.
The U.S. Food and Drug Administration on Oct. 29 authorized the Pfizer Inc. and BioNTech SE coronavirus vaccine for children aged 5 to 11 years, making it the first COVID-19 shot for young children in the United States.
The U.S. Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee recommended emergency use authorization (EUA) for the Pfizer-BioNTech vaccine for children 5 through 11 years of age, with 17 members voting yes and one abstention.
The U.S. Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee is meeting Oct. 26 to discuss and recommend an emergency use authorization for the Pfizer-BioNTech vaccine for children 5 through 11 years of age.
The World Health Organization is awaiting full clinical data on the antiviral pill made by Merck & Co. Inc. to treat mild-to-moderate Covid-19 patients, a WHO spokesperson said on Tuesday, a day after the company said it had applied for U.S. emergency use authorization.
Merck has submitted data to the U.S. Food and Drug Administration for Emergency Use Authorization (EUA) for the company’s antiviral pill molnupiravir.
A World Health Organization spokesperson said on Oct. 8 that the health agency was “near” to resolving issues on Russia’s Sputnik V Covid-19 vaccine, without giving a date for a potential emergency use listing.
Immunology is one of the more complicated areas of the life sciences, and recent studies on the long-term efficacy of the mRNA vaccines against Covid-19 are prime examples of just how complicated it can be.
Pfizer Inc. and BioNTech SE asked U.S. regulators to authorize emergency use of their Covid-19 vaccine for children ages 5 to 11, a group for whom no shot is allowed, Pfizer said on Oct. 7.
